These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31299297)

  • 1. Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Attwood M; Bowker KE; Kim A; Krause KM; MacGowan AP
    Int J Antimicrob Agents; 2019 Nov; 54(5):626-632. PubMed ID: 31299297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.
    Bowker KE; Noel AR; Tomaselli S; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 May; 73(5):1305-1313. PubMed ID: 29562340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
    Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
    Galani I; Souli M; Daikos GL; Chrysouli Z; Poulakou G; Psichogiou M; Panagea T; Argyropoulou A; Stefanou I; Plakias G; Giamarellou H; Petrikkos G
    J Chemother; 2012 Aug; 24(4):191-4. PubMed ID: 23040681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
    Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
    J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
    Zhang Y; Kashikar A; Bush K
    J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Activity of Plazomicin Against Carbapenem Resistant Klebsiella pneumoniae Strains.
    Demirbas Z; Ozger HS; Suzuk-Yildiz S; Bakkaloglu Z; Dizbay M
    Clin Lab; 2022 Jun; 68(6):. PubMed ID: 35704736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative activity of plazomicin against extended-spectrum cephalosporin-resistant Escherichia coli clinical isolates (2012-2017) in relation to phylogenetic background, sequence type 131 subclones, bla
    Johnston BD; Thuras P; Porter SB; Clabots C; Johnson JR
    Eur J Clin Microbiol Infect Dis; 2021 Oct; 40(10):2069-2075. PubMed ID: 33893571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
    Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
    Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.
    Noel AR; Bowker KE; Attwood M; MacGowan AP
    J Antimicrob Chemother; 2018 Sep; 73(9):2411-2417. PubMed ID: 30020472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of in vitro activities of plazomicin and other aminoglycosides against clinical isolates of Klebsiella pneumoniae and Escherichia coli.
    İnce G; Mirza HC; Üsküdar Güçlü A; Gümüş H; Erol Ç; Başustaoğlu A
    J Antimicrob Chemother; 2021 Nov; 76(12):3192-3196. PubMed ID: 34499728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Bactericidal Activity of Plazomicin and Comparators against Multidrug-Resistant Enterobacteriaceae.
    Thwaites M; Hall D; Shinabarger D; Serio AW; Krause KM; Marra A; Pillar C
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.
    Zhanel GG; Lawson CD; Zelenitsky S; Findlay B; Schweizer F; Adam H; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Expert Rev Anti Infect Ther; 2012 Apr; 10(4):459-73. PubMed ID: 22512755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
    Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibacterial activity of achievable epithelial lining fluid exposures of Amikacin Inhale with or without meropenem.
    So W; Crandon JL; Hamada Y; Nicolau DP
    J Antimicrob Chemother; 2016 Feb; 71(2):428-37. PubMed ID: 26559690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
    Clark JA; Kulengowski B; Burgess DS
    Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of plazomicin and other aminoglycosides against Klebsiella pneumoniae multidrug-resistant strains.
    Sękowska A
    J Antibiot (Tokyo); 2024 Aug; 77(8):548-551. PubMed ID: 38720141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.